Professor Kimme Hyrich MD PhD FRCPC

Photograph of Kimme Hyrich

Professor of Epidemiology

Arthritis Research UK Centre for Epidemiology
Centre for Musculoskeletal Research
Institute of Inflammation and Repair
The University of Manchester
Manchester Academic Health Science Centre
Room 2.809 Stopford Building
Oxford Road
M13 9PT

PA - Gillian Amroon - Telephone - 0161 275 5044 - E-mail -


I am a Professor of Epidemiology in the Arthritis Research UK Centre for Epidemiology, part of the Centre for Musculoskeletal Research and a Consultant Rheumatologist in the Kellgren Centre for Rheumatology at Central Manchester University Hospitals NHS Foundation Trust. 

I am also the Programme Director for the MRes in Medical Sciences (for intercalatintg medical students and NIHR Academic Clinical Fellows) and Epidemiology Module Lead for the MSc in Clinical Rheumatology.

I am a clinical epidemiologist and my main research interests are understanding the short and longterm outcomes in adult and childhood inflammatory arthritis, including a greater understanding of the role treatments play in these outcomes.

Memberships of Committees and Professional Bodies

Methodological Knowledge

Epidemiology and biostatistics including analysis of longterm observational cohort studies.


  • MRes in Medical Sciences -  Programme Director
  • Supervision of higher level degress (MRes, MSc and PhD)
  • Manchester Medical School - Academic Advisor
  • Epidemiology Module Lead - MSc in Clinical Rheumatology


I completed my Bachelors of Science and medical degree at the University of Manitoba in Canada. This was followed by training in internal medicine in Winnipeg, Canada and a fellowship in rheumatology at the University of Toronto. I subsequently worked as an Arthritis Society of Canada/CIHR Research Fellow at the Arthritis Research UK (formerly arc) Epidemiology Unit in Manchester, being awarded my PhD in 2005. I joined this unit as a Senior Lecturer in 2006 and  I am now  Professor of Epidemiology at the University of Manchester and an Honorary Rheumatology Consultant at the Manchester Royal Infirmary, Manchester, UK.

My main research interests centre on outcomes in inflammatory arthritis, with a particular focus on pharmacoepidemiology. I am a principal investigator for the British Society for Rheumatology Biologics Register (BSRBR), which is prospectively collecting information on all patients receiving biologic therapy for a rheumatic disease throughout the United Kingdom. Work from this project has assessed the real-world efficacy of anti-TNF agents for rheumatoid arthritis as well as predictors of response and the risk of adverse events, including infection and myocardial infarction. My research in paediatrics includes the Childhood Arthritis Prospective Study (CAPS), an inception cohort which is studying both short and long-term outcomes in children diagnosed in the UK with juvenile idiopathic arthritis and 2 biologic registers in children: the Arthritis Research UK funded Safety and Efficacy of Biologics in Children (Extended Biologics Study) and the BSPAR Etanercept Register, which is focusing on the short and long-term safety of the use of biologic drugs in children with arthritis.

I supervise a number of PhD and Masters students working on these and related projects.


  • Bachelor of Science (1992) - University of Manitoba, Canada
  • MD (1996) - University of Manitoba, Canada
  • Fellow of the Royal College of Physicians of Canada (General Medicine and Rheumatology) (2000)
  • PhD (2005) - University of Manchester, UK
  • Associate Member - Royal College of Physicians of Edinburgh (2005)

Collaborators and affiliated staff

  • Deborah Symmons (Manchester)
  • Anne Barton (Manchester)
  • Wendy Thomson (Manchester)
  • Michael Beresford (Liverpool)
  • Eileen Baildam (Liverpool)
  • Lucy Wedderburn (London)
  • Joyce Davidson (Glasgow)
  • Helen Foster (Newcastle)
  • Kath Watson (Manchester)
  • Anja Strangfeld (Berlin)
  • Angela Zink (Berlin)
  • Johan Askling (Stockholm)
  • Tim Beukleman (Birmingham, USA)
  • James Galloway (London)

Selected publications


  • Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM. (2016). Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open, 2(1), e000171. eScholarID:281463 | DOI:10.1136/rmdopen-2015-000171
  • Kearsley-Fleet L, Davies R, Baildam E, Beresford MW, Foster HE, Southwood TR, Thomson W, Hyrich KL. (2016). Factors Associated with Choice of Biologic among Children with Juvenile Idiopathic Arthritis: Results from 2 UK Paediatric Biologic Registers. Rheumatology (Oxford), [Epub ahead of print], eScholarID:280139 | DOI:10.1093/rheumatology/kev429
  • Low, A., Lunt, M., Mercer, L., Watson, K., Dixon, W., Symmons, D. & Hyrich, K (2016). Association between ischaemic stroke and tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis. Arthritis Rheumatol, [Epub ahead of print], eScholarID:294738 | PMID:26749043 | DOI:10.1002/art.39582
  • Plant D, Webster A, Nair N, Oliver J, Smith S, Eyre S, Hyrich KL, Wilson AG, Morgan AW, Isaacs J, Worthington J, Barton A. (2016). Differential methylation as a biomarker of response to etanercept in patients with rheumatoid arthritis. Arthritis Rheum, [Epub ahead of print], eScholarID:295858 | DOI:10.1002/art.39590


  • Bluett, J., Morgan, C., Cordingley, L., Barton, A., BRAGGSS, B., Thurston, L., Plant, D., Hyrich, K., Morgan, A., Wilson, A. & Isaacs, J (2015). Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford), 54(3), 494-499. eScholarID:234413 | PMID:25213131 | DOI:10.1093/rheumatology/keu358
  • Davies, R., Southwood, T., Kearsley-Fleet, L., Lunt, M., Hyrich, K. & ETN), B (2015). Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept. Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol, 67(9), 2487-2494. eScholarID:265101 | PMID:25989609 | DOI:10.1002/art.39197
  • Hyrich, K., Baildam, E., Pickford, H., Chieng, A., Davidson, J., Foster, H., Gardner-Medwin, J., Wedderburn, L. & Thomson, W (2015). Influence of past breast feeding on pattern and severity of presentation of juvenile idiopathic arthritis. A D C, [Epub ahead of print], eScholarID:267331
  • Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich KL, Barton A; BRAGGSS. (2015). Clinical utility of random anti-TNF drug level testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Arthritis Rheum, 67(8), 2011-2019. eScholarID:263348 | DOI:10.1002/art.39169
  • Kearsley-Fleet, L., Hyrich, K., Davies, R., Lunt, M. & Southwood, T (2015). Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford), [E-pub ahead of print], eScholarID:258962 | PMID:25638806 | DOI:10.1093/rheumatology/keu489
  • Kearsley-Fleet, L., Závada, J., Hetland, M., Nordström, D., Aaltonen, K., Listing, J., Zink, A., Gati, T., Rojkovich, B., Iannone, F., Gremese, E., van Riel, P., van de Laar, M., Lie, E., Kvien, T., Canhão, H., Fonseca, J., Rotar, Z., Loza, E., Carmona, L., Askling, J., Johansson, K., Finckh, A., Dixon, W. & Hyrich, K (2015). The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford), 54(6), 1074-1079. eScholarID:242324 | PMID:25433042 | DOI:10.1093/rheumatology/keu446
  • Kearsley-Fleet, Lianne; Davies, Rebecca; Lunt, Mark; Southwood, Taunton; Hyrich, Kimme. (2015). Factors Associated with Improvement in Disease Activity Following Initiation of Etanercept in Children and Young People with Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort. Rheumatology (Oxford), [Epub ahead of print], eScholarID:281693 | DOI:10.1093/rheumatology/kev434
  • Mercer, L., Lunt, M., Low, A., Dixon, W., Watson, K., Symmons, D. & Hyrich, K (2015). Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis, 74(6), 1087-1093. eScholarID:223617 | PMID:24685910 | DOI:10.1136/annrheumdis-2013-204851
  • Morgan,C.; McBeth,J.; Cordingley,L.; Watson,K.; Hyrich,K.L.;Symmons,D.P.M.;Bruce,I.N. (2015). The Influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: A study in the biologics era. Rheumatology (Oxford), 54(10), 1780-1791. eScholarID:262169
  • Radner, H., Dixon, W., Hyrich, K. & Askling, J (2015). Consistency and utility of data items across European rheumatoid arthritis clinical cohorts and registers. Arthritis Care Res (Hoboken), [Epub ahead of print], eScholarID:264590 | PMID:25892245 | DOI:10.1002/acr.22602
  • Smith SL, Eyre S, Yarwood A, Hyrich KL, Morgan AW, Wilson AG, Isaacs J, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Plant D and Barton A. (2015). Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. Arthritis Res Ther, 17, 359. eScholarID:279322 | DOI:10.1186/s13075-015-0868-y
  • Verstappen,S.M., Cobb,J., Foster,H.E., Fu,B., Baildam,E., Wedderburn,L.R., Davidson,J.E., Ioannou,J., Chieng,A., Hyrich,K.L., Thomson,W. (2015). Low socio-economic status is associated with high physical limitations and low illness self-perception in patients with juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS). Arthritis Care Res (Hoboken), 67(3), 382-389. eScholarID:232944 | PMID:25187470 | DOI:10.1002/acr.22466
  • Viatte, S., Plant, D., Han, B., Fu, B., Yarwood, A., Thomson, W., Symmons, D., Worthington, J., Young, A., Hyrich, K., Morgan, A., Wilson, A., Isaacs, J., Raychaudhuri, S. & Barton, A (2015). Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA, 313(16), 1645-56. eScholarID:263992 | PMID:25919528 | DOI:10.1001/jama.2015.3435


  • Bowes, J, Potter, C, Gibbons, LJ, Hyrich, KL, Plant, D, BRAGGSS, Morgan, A, Wilson, A, Isaacs, J, Worthington, J, Barton, A. (2009). Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics, 19(4), 319-323. eScholarID:1d19079 | DOI:10.1097/FPC.0b013e328328d51f
  • Harrison MJ, Dixon WG, Watson KD, King YE, Groves R, Hyrich KL, Symmons D, BSRBR Control Centre Consortium. (2009). Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 68(2), 209-215. eScholarID:1d17129 | DOI:10.1136/ard.2007.087288

View all publications